(Cervical Cancer) Is Keytruda Plus Platinum Chemotherapy ± Bevacizumab Effective? KEYNOTE-826 Phase 3 Results

• November 15, 2021
• 2 min read

On November 11, 2021, Nicoletta Colombo and colleagues from the University of Milan-Bicocca published results in the New England Journal of Medicine from the KEYNOTE-826 Phase 3 clinical trial evaluating the efficacy and safety of pembrolizumab (Keytruda) plus platinum-based chemotherapy ± bevacizumab as first-line treatment in patients with persistent, metastatic, or recurrent cervical cancer.

This Phase 3 trial randomized patients 1:1 to pembrolizumab (200 mg every 3 weeks) plus platinum-based chemotherapy ± bevacizumab, or placebo plus platinum-based chemotherapy ± bevacizumab. The primary endpoints were progression-free survival (PFS) and overall survival (OS).

Results:

PD-L1 positive patients (CPS ≥1, N=548):

• Median PFS: Pembrolizumab 10.4 months vs. placebo 8.2 months
• 38% reduction in death risk with pembrolizumab
• 24-month OS rate: Pembrolizumab 53.0% vs. placebo 41.7%

All patients (N=617):

• Median PFS: Pembrolizumab 10.4 months vs. placebo 8.2 months
• 35% reduction in death risk with pembrolizumab
• 24-month OS rate: Pembrolizumab 50.4% vs. placebo 40.4%

PD-L1 positive patients (CPS ≥10, N=317):

• Median PFS: Pembrolizumab 10.4 months vs. placebo 8.1 months
• 42% reduction in death risk with pembrolizumab
• 24-month OS rate: Pembrolizumab 54.4% vs. placebo 44.6%

Safety:

Most common Grade 3–5 adverse events: anemia (pembrolizumab 30.3% vs. placebo 26.9%), neutropenia (pembrolizumab 12.4% vs. placebo 9.7%).

Conclusion: Based on the KEYNOTE-826 trial results, Nicoletta Colombo and colleagues concluded that pembrolizumab plus platinum-based chemotherapy ± bevacizumab as first-line treatment significantly improved PFS and OS in patients with persistent, metastatic, or recurrent cervical cancer.

Source: https://pubmed.ncbi.nlm.nih.gov/34534429/

Cervical Cancer | Immunotherapy | Keytruda | KEYNOTE-826

• Clinical Trial Medications

• Immunotherapy

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4